Holen Sie sich die Stockscreener-App
1.01
0.98%
-0.01
Schlusskurs vom Vortag:
$1.02
Offen:
$1.05
24-Stunden-Volumen:
68,191
Relative Volume:
0.23
Marktkapitalisierung:
$46.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.78M
KGV:
-1.839
EPS:
-0.5492
Netto-Cashflow:
$-10.52M
1W Leistung:
-17.21%
1M Leistung:
+7.86%
6M Leistung:
-68.24%
1J Leistung:
-84.97%
1-Tages-Spanne:
$1.00
$1.05
1-Wochen-Bereich:
$0.9484
$1.2691
52-Wochen-Spanne:
$0.7626
$13.59
Fibrobiologics Inc Stock (FBLG) Company Profile
Firmenname
Fibrobiologics Inc
Sektor
Branche
Telefon
281-671-5150
Adresse
455 E. MEDICAL CENTER BLVD, HOUSTON
Vergleichen Sie FBLG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.01 | 46.68M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-24 | Eingeleitet | Maxim Group | Buy |
Fibrobiologics Inc Aktie (FBLG) Neueste Nachrichten
FibroBiologics Presents at the ThymUS 2025 Meeting - GlobeNewswire
FibroBiologics Research Scientist Presents Innovative Thymus Organoid Development at ThymUS 2025 Meeting - Nasdaq
Revolutionary Thymus Organoid Breakthrough: FibroBiologics Reveals New T-Cell Generation Method - Stock Titan
FibroBiologics, Inc. (NASDAQ:FBLG) Shares Acquired by Cerity Partners LLC - Defense World
FibroBiologics Inc Inc. (FBLG) Price Performance: A Technical Analysis Perspective - investchronicle.com
O Shaughnessy Asset Management LLC Acquires New Position in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
Raymond James Financial Inc. Invests $37,000 in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics’ (FBLG) Buy Rating Reiterated at D. Boral Capital - Defense World
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean - GlobeNewswire
Revolutionary Cell Therapy: FibroBiologics Unveils Multi-Disease Treatment Platform in Rome - Stock Titan
Houston Biotechnology Company Brings Manufacturing Ops Home With New Facility - Bisnow
Fibrobiologics stock plunges to 52-week low at $0.8 amid market challenges By Investing.com - Investing.com South Africa
Fibrobiologics stock plunges to 52-week low at $0.8 amid market challenges - Investing.com India
FibroBiologics opens cell therapy manufacturing space ahead of clinical trials - The Business Journals
OTC Markets Hosts Virtual Investor Presentation with Pete O'Heeron, CEO & Chairman of FibroBiologics, Inc., with David Bautz, PhD, Senior Analyst at Zacks SCR - Yahoo Finance
FibroBiologics opens new lab to boost chronic disease research By Investing.com - Investing.com South Africa
FibroBiologics opens new lab to boost chronic disease research - Investing.com
FibroBiologics announces opening of new lab facility - TipRanks
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics - The Manila Times
FibroBiologics Unveils New and Expanded Houston Laboratory - GlobeNewswire
FibroBiologics Supercharges R&D with Massive New Lab Launch: In-House Manufacturing Next - Stock Titan
Zacks Small Cap Weighs in on FibroBiologics Q1 Earnings - Defense World
FY2025 EPS Estimates for FibroBiologics Increased by Analyst - Defense World
FBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25… - Zacks Small Cap Research
HC Wainwright Comments on FibroBiologics Q1 Earnings - Defense World
FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt - GlobeNewswire Inc.
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair - GlobeNewswire
FibroBiologics announces advancement in results of brain tissue repair - TipRanks
Fibrobiologics Announces Scientific Advancement In Confirmation Results Of Brain Tissue Repair - MarketScreener
Major Breakthrough: FibroBiologics Confirms Brain Tissue Regeneration Success - Stock Titan
FibroBiologics’ (FBLG) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Virtu Financial LLC Buys New Holdings in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics’ (FBLG) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Fibrobiologics stock plunges to 52-week low at $0.93 amid market challenges By Investing.com - Investing.com South Africa
Fibrobiologics stock plunges to 52-week low at $0.93 amid market challenges - Investing.com Canada
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
FibroBiologics Slashes Annual Losses by $5.3M as Key Clinical Trial Approaches - Stock Titan
Spotting Winners: TopBuild (NYSE:BLD) And Home Builders Stocks In Q4 - The Globe and Mail
FibroBiologics Announces 2025 Annual Meeting of Stockholders - GlobeNewswire
Biotech Pioneer FibroBiologics Reveals Massive 160+ Patent Portfolio at Upcoming Shareholder Meeting - Stock Titan
Applied Industrial (AIT): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
3 Reasons to Avoid FUBO and 1 Stock to Buy Instead - The Globe and Mail
Intuitive Machines Stock (LUNR) Lifts Off with 30% Surge Post Q4 Results - The Globe and Mail
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting - GlobeNewswire
FibroBiologics Announces Presentation on Innovative Fibroblast-Based Therapeutics at The German-Nordic Joint Extracellular Matrix Meeting - Nasdaq
FBLG stock touches 52-week low at $0.98 amid sharp annual decline By Investing.com - Investing.com South Africa
FBLG stock touches 52-week low at $0.98 amid sharp annual decline - Investing.com Australia
Finanzdaten der Fibrobiologics Inc-Aktie (FBLG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
2.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):